File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1080/17425255.2018.1472236
- Scopus: eid_2-s2.0-85048015124
- PMID: 29718748
- WOS: WOS:000433949900001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: An update on the toxicological considerations for protease inhibitors used for hepatitis C infection
Title | An update on the toxicological considerations for protease inhibitors used for hepatitis C infection |
---|---|
Authors | |
Keywords | Chronic kidney disease Cirrhosis Direct acting antiviral Drug interaction Hepatitis B virus Hepatitis C virus Protease inhibitor Safety |
Issue Date | 2018 |
Publisher | Informa Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/emt |
Citation | Expert Opinion on Drug Metabolism & Toxicology, 2018, v. 14 n. 5, p. 483-491 How to Cite? |
Abstract | Introduction: Hepatitis C virus protease inhibitors (PIs) are important components of many direct acting antiviral regimens. Many clinical trials and real-world studies have described the safety data for individual PIs. We aimed to review the safety of both the first and second generation PIs in patients with chronic hepatitis C (CHC).
Areas covered: The unique pharmacokinetic properties of PIs partly explain their toxicities. Second generation PIs, when used without interferon and ribavirin, are well-tolerated. Use of PIs in renal impaired patients or those on dialysis appears to be safe. Decompensated cirrhosis is a contraindication for PIs use due to increased drug exposure and risk of liver decompensation. Drug-drug interactions are common and should be always monitored; some drugs should not be co-administered with PIs. In patients with co-infected hepatitis B virus, reactivation after DAA (whether PI-containing or not) is a concern.
Expert opinion: Second generation PIs are key players in the current DAA era. Post-marketing surveillance is essential to monitor unknown adverse events and drug–drug interactions. Non-PI based DAA should be used in decompensated liver disease. The use of these drugs should also be explored in the paediatric population. |
Persistent Identifier | http://hdl.handle.net/10722/254726 |
ISSN | 2023 Impact Factor: 3.9 2023 SCImago Journal Rankings: 0.987 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Seto, WK | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, MF | - |
dc.date.accessioned | 2018-06-21T01:05:32Z | - |
dc.date.available | 2018-06-21T01:05:32Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Expert Opinion on Drug Metabolism & Toxicology, 2018, v. 14 n. 5, p. 483-491 | - |
dc.identifier.issn | 1742-5255 | - |
dc.identifier.uri | http://hdl.handle.net/10722/254726 | - |
dc.description.abstract | Introduction: Hepatitis C virus protease inhibitors (PIs) are important components of many direct acting antiviral regimens. Many clinical trials and real-world studies have described the safety data for individual PIs. We aimed to review the safety of both the first and second generation PIs in patients with chronic hepatitis C (CHC). Areas covered: The unique pharmacokinetic properties of PIs partly explain their toxicities. Second generation PIs, when used without interferon and ribavirin, are well-tolerated. Use of PIs in renal impaired patients or those on dialysis appears to be safe. Decompensated cirrhosis is a contraindication for PIs use due to increased drug exposure and risk of liver decompensation. Drug-drug interactions are common and should be always monitored; some drugs should not be co-administered with PIs. In patients with co-infected hepatitis B virus, reactivation after DAA (whether PI-containing or not) is a concern. Expert opinion: Second generation PIs are key players in the current DAA era. Post-marketing surveillance is essential to monitor unknown adverse events and drug–drug interactions. Non-PI based DAA should be used in decompensated liver disease. The use of these drugs should also be explored in the paediatric population. | - |
dc.language | eng | - |
dc.publisher | Informa Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/emt | - |
dc.relation.ispartof | Expert Opinion on Drug Metabolism & Toxicology | - |
dc.subject | Chronic kidney disease | - |
dc.subject | Cirrhosis | - |
dc.subject | Direct acting antiviral | - |
dc.subject | Drug interaction | - |
dc.subject | Hepatitis B virus | - |
dc.subject | Hepatitis C virus | - |
dc.subject | Protease inhibitor | - |
dc.subject | Safety | - |
dc.title | An update on the toxicological considerations for protease inhibitors used for hepatitis C infection | - |
dc.type | Article | - |
dc.identifier.email | Mak, LY: lungyi@hku.hk | - |
dc.identifier.email | Seto, WK: wkseto@hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, MF: mfyuen@hku.hk | - |
dc.identifier.authority | Mak, LY=rp02668 | - |
dc.identifier.authority | Seto, WK=rp01659 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, MF=rp00479 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1080/17425255.2018.1472236 | - |
dc.identifier.pmid | 29718748 | - |
dc.identifier.scopus | eid_2-s2.0-85048015124 | - |
dc.identifier.hkuros | 285231 | - |
dc.identifier.volume | 14 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 483 | - |
dc.identifier.epage | 491 | - |
dc.identifier.isi | WOS:000433949900001 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1742-5255 | - |